05707nam 2201885z- 450 991057687430332120231214132826.0(CKB)5720000000008432(oapen)https://directory.doabooks.org/handle/20.500.12854/84569(EXLCZ)99572000000000843220202206d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierAnticancer Drugs 2021BaselMDPI - Multidisciplinary Digital Publishing Institute20221 electronic resource (594 p.)3-0365-4348-1 3-0365-4347-3 The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure–activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.Research & information: generalbicsscChemistrybicsscthymidylate synthasecytotoxicity1,2,3-triazole1,3,4-oxadiazole5-fluoruracilpemetrexeddocking3,4'-bis-guanidino3-amino-4'-guanidinodiphenyl etherphenyl pyridyl etherintramolecular hydrogen bondcancer cell viabilityHL-60BRAFapoptosisthieno[2,3-d][1,2,3]triazineacetamideH1299HER2EGFRBcl-2 inhibitorsIndole-based analoguesbenzimidazoleMTT cytotoxic assaycell cycle analysisDNA fragmentationELISAsolid/lipid nanoparticlesphenstatinletrozoletubulin polymerisation inhibitoraromatase inhibitorbreast cancerhybrid moleculedual-targeting moleculedesigned multiple ligandNaMSAcyclophosphamidehistopathologytestisurinary bladderanticancer agentsenantioselective synthesisgastric adenocarcinomatryptophanolconcentration-guided dosingmodel informed dosingphysiologically based pharmacokineticssorafenibtyrosil-DNA-phosphodiesterase 1adamantaneresin acidTDP1cytotoxic agentsapoptosis inductionHT-29 cellsMDA-MB-231 cellsmechanism predictionSTAT inhibitorsmiR-21hydrazide derivativesnitrogen scaffoldsmitoxantronecardiotoxicityinflammationoxidative stressagecumulative doseTrkNTRKtissue-agnosticlarotrectinibentrectinibTrk fusionprotein kinase inhibitorsUSFDAcancerpatent reviewgeneric productdoxazosinMD simulationscombretastatin A-4cytotoxic activityhybrid compoundsindazolemucinMUC1MUC16immunotherapycancer vaccineCAR (chimeric antigen receptor)ADC (antibody-drug conjugate)thioureainterleukin-6trypan blue assaychalconesexportin-1covalent bindingCovDockanticancer activityxanthonein vitroin vivoisolationsynthesisheterocyclic compoundbenzenesulfonamidesimidazolesalkylatedcolony formationtumor spheroidsHDAC inhibitorschalconedual inhibitorscarvedilolkidneytoxicity7-deaza-4'-thioadenosine derivativesmulti-kinase inhibitoranticancernucleosideImiquimoddrug effluxmultidrug resistanceToll-Like ReceptorResearch & information: generalChemistryMeegan Mary Jedt1325230O'Boyle Niamh MedtMeegan Mary JothO'Boyle Niamh MothBOOK9910576874303321Anticancer Drugs 20213036711UNINA